Journal of Clinical Endocrinology & Metabolism, Vol 68, 715-720, Copyright © 1989 by Endocrine Society

ARTICLES

The relative contributions of hepatic and peripheral tissues to insulin resistance in hyperandrogenic women

AN Peiris, EJ Aiman, WD Drucker and AH Kissebah
Clinical Research Center, Medical College of Wisconsin, Milwaukee 53226.

Insulin resistance is associated with hyperandrogenic states. To determine the mechanisms by which androgen excess can affect insulin action, we studied insulin sensitivity in five nonobese hyperandrogenic women and six normal women. After oral glucose administration, the hyperandrogenic women had higher serum insulin concentrations than the normal women (P = 0.05). The mean cumulative peripheral serum insulin response in the hyperandrogenic women [79.6 +/- 30.8 (+/- SD) nmol/L.300 min] was significantly greater than that in the normal women (46.6 +/- 15.1 nmol/L.300 min; P less than 0.05). In the basal state and during hyperinsulinemic (20 mU/min.m2) euglycemic clamp studies serum insulin levels were similar in the two groups. Basal and insulin- mediated suppressions of hepatic glucose production determined from [3- 3H]glucose specific activity were similar in the two groups. Peripheral glucose utilization was markedly diminished in the hyperandrogenic women compared to that in the normal women (27.8 +/- 6.7 vs 48.9 +/- 12.8 mumol/min.kg fat-free mass; P less than 0.01). We conclude that the insulin resistance in nonobese hyperandrogenic women is due to peripheral, but not hepatic, resistance to the action of insulin. This marked peripheral insulin resistance may result from the effects of hyperandrogenemia on skeletal muscle fiber morphology and metabolism.

This article has been cited by other articles:

				G. Schillaci, M. Pirro, G. Pucci, M. R. Mannarino, F. Gemelli, D. Siepi, G. Vaudo, and E. Mannarino Different Impact of the Metabolic Syndrome on Left Ventricular Structure and Function in Hypertensive Men and Women Hypertension, May 1, 2006; 47(5): 881 - 886. [Abstract] [Full Text] [PDF]

				B. Iglseder, P. Cip, L. Malaimare, G. Ladurner, and B. Paulweber The Metabolic Syndrome Is a Stronger Risk Factor for Early Carotid Atherosclerosis in Women Than in Men Stroke, June 1, 2005; 36(6): 1212 - 1217. [Abstract] [Full Text] [PDF]

				E. Diamanti-Kandarakis, C. Kouli, K. Alexandraki, and G. Spina Failure of Mathematical Indices to Accurately Assess Insulin Resistance in Lean, Overweight, or Obese Women with Polycystic Ovary Syndrome J. Clin. Endocrinol. Metab., March 1, 2004; 89(3): 1273 - 1276. [Abstract] [Full Text] [PDF]

				J. Vrbikova, B. Bendlova, M. Hill, M. Vankova, K. Vondra, and L. Starka Insulin Sensitivity and {beta}-Cell Function in Women With Polycystic Ovary Syndrome Diabetes Care, July 1, 2002; 25(7): 1217 - 1222. [Abstract] [Full Text] [PDF]

				I. Ek, P. Arner, M. Ryden, C. Holm, A. Thorne, J. Hoffstedt, and H. Wahrenberg A Unique Defect in the Regulation of Visceral Fat Cell Lipolysis in the Polycystic Ovary Syndrome as an Early Link to Insulin Resistance Diabetes, February 1, 2002; 51(2): 484 - 492. [Abstract] [Full Text] [PDF]

				E. Diamanti-Kandarakis, G. Spina, C. Kouli, and I. Migdalis Increased Endothelin-1 Levels in Women with Polycystic Ovary Syndrome and the Beneficial Effect of Metformin Therapy J. Clin. Endocrinol. Metab., October 1, 2001; 86(10): 4666 - 4673. [Abstract] [Full Text] [PDF]

				G. Gennarelli, J. Holte, L. Berglund, C. Berne, M. Massobrio, and H. Lithell Prediction models for insulin resistance in the polycystic ovary syndrome Hum. Reprod., October 1, 2000; 15(10): 2098 - 2102. [Abstract] [Full Text] [PDF]

				P. J. Marsden, A. P. Murdoch, and R. Taylor Adipocyte insulin action in hypogonadotrophic hypogonadism Hum. Reprod., August 1, 2000; 15(8): 1672 - 1678. [Abstract] [Full Text] [PDF]

				M. Niklasson, P. Daneryd, P. Lonnroth, and A. Holmang Effects of exercise on insulin distribution and action in testosterone-treated oophorectomized female rats J Appl Physiol, June 1, 2000; 88(6): 2116 - 2122. [Abstract] [Full Text] [PDF]

				L. C. Morin-Papunen, I. Vauhkonen, R. M. Koivunen, A. Ruokonen, and J. S. Tapanainen Insulin sensitivity, insulin secretion, and metabolic and hormonal parameters in healthy women and women with polycystic ovarian syndrome Hum. Reprod., June 1, 2000; 15(6): 1266 - 1274. [Abstract] [Full Text] [PDF]

				D. Jaquet, J. Leger, D. Chevenne, P. Czernichow, and C. Levy-Marchal Intrauterine Growth Retardation Predisposes to Insulin Resistance But Not to Hyperandrogenism in Young Women J. Clin. Endocrinol. Metab., November 1, 1999; 84(11): 3945 - 3949. [Abstract] [Full Text]

				A. Cagnacci, A.M. Paoletti, S. Arangino, G.B. Melis, and A. Volpe Effect of ovarian suppression on glucose metabolism of young lean women with and without ovarian hyperandrogenism Hum. Reprod., April 1, 1999; 14(4): 893 - 897. [Abstract] [Full Text] [PDF]

				I. Ek, P. Arner, A. Bergqvist, K. Carlstrom, and H. Wahrenberg Impaired Adipocyte Lipolysis in Nonobese Women with the Polycystic Ovary Syndrome: A Possible Link to Insulin Resistance? J. Clin. Endocrinol. Metab., April 1, 1997; 82(4): 1147 - 1153. [Abstract] [Full Text] [PDF]

				B. Andersson, L.-A. Mattsson, L. Hahn, L. Lapidus, G. Holm, B.-A. Bengtsson, and P. Bjorntorp Estrogen Replacement Therapy Decreases Hyperandrogenicity and Improves Glucose Homeostasis and Plasma Lipids in Postmenopausal Women With Noninsulin-Dependent Diabetes Mellitus J. Clin. Endocrinol. Metab., February 1, 1997; 82(2): 638 - 643. [Abstract] [Full Text] [PDF]

				S. Franks Polycystic Ovary Syndrome N. Engl. J. Med., September 28, 1995; 333(13): 853 - 861. [Full Text] [PDF]